LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.

about

Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.

P2860

Q52580579-9101F25A-2930-466F-B46E-13BD141453E4

P2860

LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.

Item

http://www.wikidata.org/entity/Q49899858

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

LY2963016 Insulin Glargine and ...... codynamics at Two Dose Levels.

@en

LY2963016 Insulin Glargine and Insulin Glargine

@nl

type

Item

label

LY2963016 Insulin Glargine and ...... codynamics at Two Dose Levels.

@en

LY2963016 Insulin Glargine and Insulin Glargine

@nl

prefLabel

LY2963016 Insulin Glargine and ...... codynamics at Two Dose Levels.

@en

LY2963016 Insulin Glargine and Insulin Glargine

@nl

P1476

LY2963016 Insulin Glargine and ...... codynamics at Two Dose Levels.

@en

P2093

Danny Soon

http://www.w3.org/2001/XMLSchema#string

David Coutant

http://www.w3.org/2001/XMLSchema#string

Eric Chen Quin Lam

http://www.w3.org/2001/XMLSchema#string

Helle Linnebjerg

http://www.w3.org/2001/XMLSchema#string

Lai Hock Tan

http://www.w3.org/2001/XMLSchema#string

Laiyi Chua

http://www.w3.org/2001/XMLSchema#string

Mary E Seger

http://www.w3.org/2001/XMLSchema#string

Xin Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.

Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.

Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

P304

556-563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPDD.392

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28940840

http://www.w3.org/2001/XMLSchema#string

LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.

about

P2860

P2860

LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698